In this study, we examined the ability of IS-SNAs to induce antitumor CD8+ T cell immune responses against three well-established prostate tumor-associated antigens (TAAs): prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate acidic phosphatase (PAP). The gene discussed is CD8A; the disease is prostate neoplasm.